The Asia Pacific Dry Eye Syndrome Treatment Market would witness market growth of 5.4% CAGR during the forecast period (2022-2028).
Techniques and examinations have developed that could be used to identify the reason for dry eyes. The doctor can identify the reason for dry eyes with the use of an eye test that includes a thorough history of general health and eye health. The Schirmer test may be used by the physician to gauge tear production. Under the lower eyelids are positioned blotting paper strips for this procedure. The doctor counts how much of the strip has been saturated with tears after five minutes. Another test to gauge DED is phenol red thread test which is an additional method for calculating tear volume.
In this test, the lower eyelid is covered with a thread containing a pH-sensitive dye. The dye is soaked with tears for 15 seconds, after which the tear volume is determined. The amount of water and particle content in tears is determined by a test called tear osmolarity. Less water will be present in the eyes if one has a dry eye illness. A doctor can also look for dry eye disease signs in tear samples, such as decreased lactoferrin or increased matrix metalloproteinase-9.
Two population-based research, two cross-sectional surveys on users of visual display terminals (VDTs), and one study that specifically targeted high school students have all been conducted to evaluate the epidemiological component of DED in Japan. In two studies, the indirect cost of DED was evaluated using an evaluation of job productivity, while the direct cost of DED was calculated in one study. In all investigations, the rate of DED in the Japanese population was significantly high in comparison to data from other nations. It was calculated that patients with definite DED would lose between $741 and $6160 in terms of work productivity. There has been a sharp increase in research and development operations to create novel medications for the efficient treatment of dry eye remedial solutions.
The China market dominated the Asia Pacific Dry Eye Syndrome Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $564.2 million by 2028. The Japan market is showcasing a CAGR of 4.7% during (2022 - 2028). Additionally, The India market would register a CAGR of 6% during (2022 - 2028).
Based on Type, the market is segmented into Evaporative Dry Eye Syndrome and Aqueous Deficient Dry Eye Syndrome. Based on Drug, the market is segmented into Restasis, Xiidra, Cequa, Eysuvis and Tyrvaya & Others. Based on Dosage, the market is segmented into Eye drops, Gels, Capsules & Tablets, Eye Solutions and Ointments. Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy and Online Pharmacy. Based on Sales Channel, the market is segmented into OTC and Prescription. Based on Product, the market is segmented into Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, Oral Omega Supplements and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Dry Eye Syndrome Treatment Market is Projected to reach USD 6.5 Billion by 2028, at a CAGR of 4.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson (Johnson & Johnson Services, Inc.), AbbVie, Inc., Bausch + Lomb Corporation (Bausch Health Companies, Inc.), Novartis AG, Sun Pharmaceuticals Industries Ltd., AFT Pharmaceuticals, Santen Pharmaceutical Co., Ltd., Oyster Point Pharma, Inc., OASIS Medical, Inc., and Otsuka Pharmaceutical Co., Ltd.
By Type
By Drug
By Dosage
By Distribution Channel
By Sales Channel
By Product
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
